BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23061481)

  • 1. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
    Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.
    Barraud de Lagerie S; Comets E; Gautrand C; Fernandez C; Auchere D; Singlas E; Mentre F; Gimenez F
    Br J Pharmacol; 2004 Apr; 141(7):1214-22. PubMed ID: 15023856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.
    Nieto Montesinos R; Béduneau A; Lamprecht A; Pellequer Y
    Mol Pharm; 2015 Nov; 12(11):3829-38. PubMed ID: 26390138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution.
    Montesinos RN; Moulari B; Gromand J; Beduneau A; Lamprecht A; Pellequer Y
    Drug Metab Dispos; 2014 Apr; 42(4):700-6. PubMed ID: 24398461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.
    Choo EF; Kurnik D; Muszkat M; Ohkubo T; Shay SD; Higginbotham JN; Glaeser H; Kim RB; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1012-8. PubMed ID: 16537797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.
    Cutler L; Howes C; Deeks NJ; Buck TL; Jeffrey P
    J Pharm Sci; 2006 Sep; 95(9):1944-53. PubMed ID: 16850390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
    Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.
    Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
    Drug Metab Dispos; 1999 Jul; 27(7):827-34. PubMed ID: 10383928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J; Pollack GM
    J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study.
    Chan GN; Saldivia V; Yang Y; Pang H; de Lannoy I; Bendayan R
    J Neurochem; 2013 Nov; 127(3):342-52. PubMed ID: 23777437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.
    Padowski JM; Pollack GM
    Brain Res; 2011 Dec; 1426():1-17. PubMed ID: 22036081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
    Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
    Bachmeier CJ; Trickler WJ; Miller DW
    Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits.
    Senthilkumari S; Velpandian T; Biswas NR; Saxena R; Ghose S
    Curr Eye Res; 2008 Apr; 33(4):333-43. PubMed ID: 18398708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
    Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
    Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
    Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
    Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.